Main Conference – Day 1Wednesday, 18 March 2026 - CET (Central European Time, GMT+01:00)

Data will be presented validating two Argonaute dual targeting siRNAs (bis-siRNAs), respectively addressing residual risk/unmet need for ASCVD, including heart attacks and stroke, and fatty liver diseases (MASLD/MASH). We will present compelling and comprehensive results from in vitro and large in vivo studies, including extensive biochemical, gene expression and metabolomics assays demonstrating the extraordinary efficacy and safety of these agents. Together a strong case will be made for pursuing clinical development of these agents with the aim of launching first in man studies in the next 12-18 months.